INTRODUCTION {#s1}
============

Cancer of the urinary bladder is the fourth most common malignancy in men and the ninth most common malignancy in women in the United States \[[@R1]\]. Urothelial carcinomas constitute approximately 90% of all bladder cancer (BCa) cases \[[@R2]\]. At presentation, more than 80% of bladder tumors are non-muscle invasive bladder cancer (NMIBC, *i.e.,* Tis, Ta or T1) and the remaining 20% of bladder tumors are muscle-invasive bladder cancers (MIBC) or metastatic. NMIBC harbors a 5-year survival rate of approximately 94% \[[@R3], [@R4]\]; however, approximately 70% of patients with these lesions develop tumor recurrence within two years of initial diagnosis. The recurrence phenomenon of NMIBC makes it one of the most prevalent cancers worldwide; in America, it is second only to colorectal cancer. Therefore, NMIBC is a significant burden to healthcare systems \[[@R1], [@R5]\]. As for MIBC, 5-year survival rate is approximately 50%, which drops off to \< 20% in the case of metastatic disease \[[@R6], [@R7]\].

Methods to identify NMIBC and MIBC patients, who are at increased risk of disease recurrence and succumbing to disease, have previously relied on conventional histopathologic evaluation. These histopathologic features have failed to properly risk stratify these patients. Thus, prognostic markers are urgently needed to identify high-risk patients who would benefit from early radical treatment and/or neoadjuvant or adjuvant therapies.

In our previous studies, we have coupled high-throughput, discovery-based technology (*i.e.,* genomics and proteomics) with bioinformatics, in order to derive a BCa-associated diagnostic signature that shows promise for the accurate detection of BCa in voided urine samples \[[@R8]--[@R11]\]. In five independent studies, we have validated our 10 biomarkers, which comprise our BCa-associated diagnostic signature \[[@R12]--[@R16]\]. Additionally, we have reported the prognostic significance of two of the 10 biomarkers that comprise the BCa-associated diagnostic signature, angiogenin (ANG) and plasminogen activator inhibitor-1 (PAI-1) \[[@R17]--[@R20]\]. Furthermore, in-depth molecular analyses of ANG and PAI-1 have identified other key molecules that possess a significant downstream or upstream interplay with them (*i.e.,* MMP-2 and p53 with ANG and RB and p53 with PAI-1) \[[@R17]-[@R19], [@R21]\].

In the present study, we set out to validate the tissue expression of ANG, MMP-2, p53, PAI-1 and RB in human BCa with immunohistochemistry conducted on tissue microarrays (TMA). Demographic, clinical, disease and treatment characteristics are presented in Table [1](#T1){ref-type="table"}. The aims of the validation were to a) analyze the tissue immunoreactivity of these BCa candidate biomarkers and b) investigate if the expression of these BCa candidate biomarkers possesses prognostic value in determining recurrence-free survival and overall survival in BCa patients.

###### Demographic, clinical, and pathologic characteristics of the 939 subjects comprising the study cohort

  -----------------------------------------------------------
  Features            Denmark\    Sweden\     All Patients\
                      N = 587     N = 352     N = 939
  ------------------- ----------- ----------- ---------------
  Age (years)                                 

   ≤ 65               274 (47%)   90 (26%)    364 (39%)

   \> 65              313 (53%)   256 (73%)   569 (61%)

   Unavailable        0 ( 0%)     6 ( 2%)     6 ( 1%)

  Gender                                      

   Female             144 (25%)   85 (24%)    229 (24%)

   Male               443 (75%)   264 (75%)   707 (75%)

   Unavailable        0 ( 0%)     3 ( 1%)     3 ( 0%)

  Tumor Grade                                 

   Low                139 (24%)   84 (24%)    223 (24%)

   High               437 (74%)   265 (75%)   702 (75%)

   Unavailable        11 ( 2%)    3 ( 1%)     14 ( 1%)

  Tumor Stage                                 

   Ta or Tis          139 (24%)   119 (34%)   258 (27%)

   T1                 133 (23%)   117 (33%)   250 (27%)

   T2                 294 (50%)   89 (25%)    383 (41%)

   T3 or T4           21 ( 4%)    23 ( 7%)    44 ( 5%)

   Unavailable        0 ( 0%)     4 ( 1%)     4 ( 0%)

  Lymph Nodes                                 

   N0 or Nx           470 (80%)   341 (97%)   811 (86%)

   N1                 117 (20%)   11 ( 3%)    128 (14%)

  Progression                                 

   No                 318 (54%)   230 (65%)   548 (58%)

   Yes                269 (46%)   110 (31%)   379 (40%)

   Unavailable        0 ( 0%)     12 ( 3%)    12 ( 1%)

  Follow-up (years)                           

   Median             6.83        3.75        5.37
  -----------------------------------------------------------

RESULTS {#s2}
=======

P53, RB and PAI-1 are preferentially associated with aggressive bladder cancer {#s2_1}
------------------------------------------------------------------------------

Figure [1](#F1){ref-type="fig"} shows representative immunohistochemical stainings for each of the five targets in a high-grade non-muscle invasive tumor. The relationship between immunophenotype for each target and tumor grade is summarized in Table [2](#T2){ref-type="table"}. We found the highest expression levels of p53, RB and PAI-1 (total staining score ≥3) associated with high-grade disease compared to low-grade disease (58% *vs.* 27%, 85% *vs.* 65%, 65% *vs.* 49%, respectively). Furthermore, the highest expression of MMP-2 was noted with low-grade disease compared to high-grade disease (64% *vs.* 52%). These differences were statistically significant. The relationships between immunophenotype for each target and tumor stage are summarized in Table [3](#T3){ref-type="table"}. We found the highest expression levels of p53 and RB in T2 stage tumors (compared to Ta/Tis stage tumors (62% *vs.* 29% and 87% *vs.* 68%, respectively). Similar to its expression in low-grade tumors, MMP-2 expression was higher in Ta/Tis stage tumors compared to T2 stage tumors (62% *vs.* 47%). These differences were statistically significant. However, we observed no difference in p53, RB and MMP-2 expression between T2 and T3/T4 stage tumors.

![Representative expression status for ANG, MMP-2, p53, RB and PAI-1 in a high-grade non-muscle invasive bladder cancer\
Upper row represents high intensity while lower row represents low intensity associated with each target. All images were captured at 400× magnification.](oncotarget-08-99707-g001){#F1}

###### Relationship between immunochemical features and tumor grade

  Target Expression   Low-Grade N (Column %)   High-Grade N (Column %)   *p*-value^\*^
  ------------------- ------------------------ ------------------------- ---------------
  ANG                                                                    
   0-2                181 (93%)                547 (92%)                 .64
   3-4                13 ( 7%)                 48 ( 8%)                  
   5-6                0 ( 0%)                  0 ( 0%)                   
  MMP-2                                                                  
   0-2                75 (36%)                 286 (48%)                 .01
   3-4                129 (63%)                306 (51%)                 
   5-6                2 ( 1%)                  6 ( 1%)                   
  p53                                                                    
   0-2                158 (73%)                270 (42%)                 \<.0001
   3-4                55 (25%)                 301 (46%)                 
   5-6                5 ( 2%)                  78 (12%)                  
  Rb                                                                     
   0-2                46 (23%)                 89 (15%)                  .008
   3-4                152 (76%)                508 (83%)                 
   5-6                1 ( 1%)                  13 ( 2%)                  
  PAI-1                                                                  
   0-2                108 (51%)                228 (35%)                 \<.0001
   3-4                103 (48%)                400 (62%)                 
   5-6                2 ( 1%)                  22 ( 3%)                  

^\*^Fisher's Exact Test.

###### Relationship between immunochemical features and tumor stage

  Target Expression   Ta or Tis N (Column %)   T1 N (Column %)   T2 N (Column %)   T3 or T4 N (Column %)   *p*-value^\*^
  ------------------- ------------------------ ----------------- ----------------- ----------------------- ---------------
  ANG                                                                                                      
   0-2                212 (93%)                204 (94%)         283 (90%)         35 (92%)                .28
   3-4                17 (7%)                  12 (6%)           32 (10%)          3 ( 8%)                 
   5-6                0 (0%)                   0 (0%)            0 (0%)            0 ( 0%)                 
  MMP-2                                                                                                    
   0-2                91 (38%)                 86 (38%)          170 (55%)         21 (55%)                \<.0001
   3-4                147 (61%)                140 (62%)         132 (43%)         17 (45%)                
   5-6                2 (1%)                   0 (0%)            6 (2%)            0 ( 0%)                 
  p53                                                                                                      
   0-2                178 (71%)                112 (47%)         129 (38%)         11 (26%)                \<.0001
   3-4                68 (27%)                 107 (45%)         160 (47%)         25 (58%)                
   5-6                6 (2%)                   18 ( 8%)          53 (15%)          7 (16%)                 
  Rb                                                                                                       
   0-2                57 (24%)                 40 (18%)          36 (11%)          3 ( 8%)                 .0001
   3-4                174 (75%)                181 (82%)         276 (86%)         35 (88%)                
   5-6                2 (1%)                   1 (0%)            9 (3%)            2 ( 5%)                 
  PAI-1                                                                                                    
   0-2                109 (44%)                85 (36%)          133 (38%)         9 (23%)                 .04
   3-4                136 (55%)                147 (62%)         199 (57%)         30 (75%)                
   5-6                4 ( 2%)                  4 (2%)            15 (4%)           1 ( 3%)                 

^\*^Fisher's Exact Test.

MMP-2, p53, RB, PAI-1 are associated with a reduction in recurrence-free survival and overall survival in bladder cancer {#s2_2}
------------------------------------------------------------------------------------------------------------------------

In NMIBC, univariate analysis indicated that age, tumor grade, tumor stage (Ta/Tis *vs.* T1), expression of p53 and RB predicted progression-free survival. With multivariate analysis, \>65 years of age (HR 1.67, 95% CI 1.16-2.40, *p* = 0.006) and high-grade tumor (HR 1.74, 95% CI 1.04-2.92, *p* = 0.03) independently predicted a worse progression-free survival (Table [4a](#T4a){ref-type="table"}). In MIBC, univariate analysis found that age, gender, expression of MMP-2, RB and PAI-1 predicted progression-free survival. With multivariate analysis, \>65 years of age (HR 1.26, 95% CI 1.00-1.58, *p* = 0.05), high MMP-2 expression (HR 2.03, 95%CI 1.28-3.22, *p* = 0.003) and high RB expression (HR 2.31, 95%CI 1.26-4.23, *p* = 0.007) independently predicted a worse progression-free survival (Table [4b](#T4b){ref-type="table"}). Using the Kaplan-Meier survival analysis with the log-rank test, we found significantly reduced progression-free survival in NMIBC but not in MIBC when more of the five biomarkers were expressed in a tumor (*p* = 0.01 and *p* = 0.16, respectively), Figure [2a](#F2){ref-type="fig"} and [2b](#F2){ref-type="fig"}. As noted in Table [4](#T4a){ref-type="table"}, three of the five biomarkers (MMP-2, RB and PAI-1) were critical biomarkers influencing survival analysis of NMIBC and MIBC. We noted no difference in cancer-specific survival in NMIBC or MIBC associated with the expression of these five biomarkers ([Supplementary Figure 1a and 1b](#SD1){ref-type="supplementary-material"} and [Supplementary Table 1a and 1b](#SD1){ref-type="supplementary-material"}). Lastly, in NMIBC, univariate analysis demonstrated that age, gender, tumor grade, tumor stage (Ta/Tis *vs.* T1) and expression of MMP-2, RB and PAI-1 predicted overall survival (OS). With multivariate analysis, \>65 years of age (HR 2.41, 95% CI 1.78-3.26, *p* \< 0.0001), high-grade tumor (HR 2.11, 95% CI 1.43-3.12, *p* = 0.0002) and high expression of MMP-2 (HR 1.87, 95% CI 1.08-3.26, *p* = 0.03), RB (HR 3.08, 95% CI 1.79-5.32, *p* = 0.0001) and PAI-1 (HR 2.58, 95% CI 1.52-4.38, *p* = 0.0004) independently predicted a worse OS (Table [5a](#T5a){ref-type="table"}). Similarly, in MIBC, univariate analysis revealed that age, gender, lymph nodes stage (N0/NX *vs.* N1) and expression of MMP-2, RB and PAI-1 predicted overall survival (OS). With multivariate analysis, \>65 years of age (HR 1.38, 95% CI 1.10-1.74, *p* = 0.006), lymph nodes N1 stage (HR 1.40, 95% CI 1.0.9-1.80, *p* = 0.009) and high expression of MMP-2 (HR 2.08, 95% CI 1.29-3.33, *p* = 0.03), RB (HR 2.18, 95% CI 1.15-4.13, *p* = 0.02) and PAI-1 (HR 1.69, 95% CI 1.09-2.62, *p* = 0.02) independently predicted a worse OS (Table [5b](#T5b){ref-type="table"}), while male gender (HR 0.68, 95% CI 0.54-0.86, *p* = 0.002) independently predicted better OS. Using the Kaplan-Meier survival analysis with the log-rank test, we noted a significant reduction in OS in both NMIBC and MIBC as more of the five biomarkers were expressed in a tumor (*p* = 0.001 and *p* = 0.03, respectively), Figure [3a](#F3){ref-type="fig"} and [3b](#F3){ref-type="fig"}. Thus, the overall, high expression of MMP-2, RB and/or PAI-1 in bladder tumors was a marker of poor prognosis.

###### Progression Free Results for Non-Muscle Invasive Bladder Cancer

                Univariate Analyses^1^   Multivariate Analyses^1^                                                                     
  ------------- ------------------------ -------------------------- ------ ------ ------- --------- ----- ------ ------ ------ ------ ---------
  Age (years)                                                                                                                         
   ≤ 65         183                      41.7                       1.00                            181   36.8   1.00                 
   \> 65        317                      14.6                       1.84   1.29   2.63    .0008     317   15.9   1.67   1.16   2.40   .006
  Gender                                                                                                                              
   Female       95                       21.2                       1.00                            95    18.2   1.00                 
   Male         405                      22.1                       0.98   0.66   1.46    .92       403   22.6   0.88   0.59   1.32   .54
  Tumor Grade                                                                                                                         
   Low          219                      50.5                       1.00                            219   36.2   1.00                 
   High         279                      11.4                       2.47   1.74   3.52    \<.0001   279   14.5   1.74   1.04   2.92   .03
  Tumor Stage                                                                                                                         
   Ta or Tis    253                      44.6                       1.00                            252   27.8   1.00                 
   T1           247                      11.0                       2.34   1.68   3.27    \<.0001   246   16.7   1.42   0.87   2.33   .16
  Lymph Nodes                                                                                                                         
   N0 or N~X~   487                      23.5                       1.00                            486   22.8   1.00                 
   N1           13                       1.3                        5.98   3.22   11.11   \<.0001   12    2.8    4.25   2.20   8.21   \<.0001
  ANG                                                                                                                                 
   0-2          408                      25.6                       1.00                            408   24.3   1.00                 
   3-4          29                       22.9                       1.08   0.55   2.13    .83       28    26.2   0.97   0.47   2.00   .92
  MMP-2                                                                                                                               
   0-2          175                      26.1                       1.00                            173   25.5   1.00                 
   3-4          281                      21.6                       1.06   0.75   1.49    .75       281   20.4   1.09   0.77   1.55   .63
   5-6          2                        17.8                       1.12   0.56   2.22              2     16.2   1.19   0.59   2.39   
  p53                                                                                                                                 
   0-2          284                      29.8                       1.00                            284   23.6   1.00                 
   3-4          173                      18.3                       1.33   1.01   1.75    .04       173   21.5   1.08   0.81   1.44   .60
   5-6          24                       11.3                       1.77   1.03   3.06              24    19.5   1.17   0.65   2.08   
  Rb                                                                                                                                  
   0-2          97                       23.6                       1.00                            96    22.4   1.00                 
   3-4          347                      27.4                       0.93   0.62   1.40    .74       347   28.0   0.89   0.58   1.35   .58
   5-6          3                        31.7                       0.87   0.38   1.97              3     35.1   0.79   0.34   1.83   
  PAI-1                                                                                                                               
   0-2          192                      20.8                       1.00                            191   17.3   1.00                 
   3-4          277                      22.2                       0.89   0.65   1.23    .49       277   26.0   0.72   0.51   1.02   .06
   5-6          8                        23.6                       0.80   0.42   1.50              8     39.2   0.52   0.26   1.03   

^1^Univariate analyses are unadjusted. Multivariate analyses are adjusted for age, sex, tumor grade, tumor stage, and lymph nodes.

^2^Median is the median years progression free as estimated from a parametric model.

^3^HR is the hazard ratio from a semiparametric (Cox proportional hazards) model. The 95% confidence limits (LCL and UCL) are shown.

^4^The expression p-values are for trend.

###### Progression Free Results for Muscle Invasive Bladder Cancer

                Univariate Analyses^1^   Multivariate Analyses^1^                                                                   
  ------------- ------------------------ -------------------------- ------ ------ ------ --------- ----- ----- ------ ------ ------ ---------
  Age (years)                                                                                                                       
   ≤ 65         176                      3.8                        1.00                           176   3.5   1.00                 
   \> 65        248                      2.4                        1.30   1.04   1.63   .02       248   2.4   1.26   1.00   1.58   .05
  Gender                                                                                                                            
   Female       130                      2.0                        1.00                           130   1.9   1.00                 
   Male         297                      3.4                        0.71   0.56   0.89   .003      294   3.4   0.68   0.54   0.86   .001
  Tumor Stage                                                                                                                       
   T2           382                      3.0                        1.00                           381   2.9   1.00                 
   T3 or T4     44                       2.6                        1.06   0.75   1.49   .76       43    2.5   1.07   0.75   1.53   .72
  Lymph Nodes                                                                                                                       
   N0 or N~X~   312                      3.8                        1.00                           309   3.8   1.00                 
   N1           115                      1.3                        1.99   1.56   2.54   \<.0001   115   1.3   2.01   1.57   2.57   \<.0001
  ANG                                                                                                                               
   0-2          318                      3.1                        1.00                           315   3.0   1.00                 
   3-4          35                       1.5                        1.43   0.97   2.11   .07       35    1.5   1.40   0.95   2.07   .09
  MMP-2                                                                                                                             
   0-2          190                      4.0                        1.00                           189   3.9   1.00                 
   3-4          150                      2.3                        1.40   1.12   1.74   .003      148   2.2   1.43   1.13   1.80   .003
   5-6          6                        1.4                        1.95   1.25   3.04             6     1.3   2.03   1.28   3.22   
  p53                                                                                                                               
   0-2          140                      2.4                        1.00                           140   2.5   1.00                 
   3-4          186                      3.1                        0.88   0.74   1.04   .13       183   2.9   0.91   0.77   1.08   .30
   5-6          59                       4.0                        0.77   0.55   1.08             59    3.5   0.83   0.59   1.17   
  Rb                                                                                                                                
   0-2          39                       5.5                        1.00                           38    5.6   1.00                 
   3-4          311                      2.8                        1.40   1.02   1.93   .04       309   2.7   1.52   1.12   2.06   .007
   5-6          11                       1.4                        1.96   1.04   3.72             11    1.3   2.31   1.26   4.23   
  PAI-1                                                                                                                             
   0-2          143                      3.9                        1.00                           142   3.4   1.00                 
   3-4          228                      2.5                        1.29   1.04   1.58   .02       226   2.6   1.19   0.96   1.48   .11
   5-6          16                       1.6                        1.66   1.09   2.51             16    1.9   1.42   0.92   2.19   

^1^Univariate analyses are unadjusted. Multivariate analyses are adjusted for age, sex, tumor stage, and lymph nodes.

^2^Median is the median years progression free as estimated from a parametric model.

^3^HR is the hazard ratio from a semiparametric (Cox proportional hazards) model. The 95% confidence limits (LCL and UCL) are shown.

^4^The expression p-values are for trend.

![Progression-free survival analysis of 939 patients with bladder cancer\
Progression-free survival according to immunostaining status of ANG, MMP-2, p53, RB and PAI-1 in NMIBC **(A)** and MIBC **(B)**.](oncotarget-08-99707-g002){#F2}

###### Overall Survival Results for Non-Muscle Invasive Bladder Cancer

                Univariate Analyses^1^   Multivariate Analyses^1^                                                                    
  ------------- ------------------------ -------------------------- ------ ------ ------ --------- ----- ------ ------ ------ ------ ---------
  Age (years)                                                                                                                        
   ≤ 65         183                      16.7                       1.00                           181   15.4   1.00                 
   \> 65        317                      7.4                        2.59   1.93   3.48   \<.0001   317   7.5    2.41   1.78   3.26   \<.0001
  Gender                                                                                                                             
   Female       95                       10.8                       1.00                           95    10.2   1.00                 
   Male         405                      9.6                        1.14   0.82   1.58   .44       403   9.7    1.07   0.77   1.49   .68
  Tumor Grade                                                                                                                        
   Low          219                      14.2                       1.00                           219   14.0   1.00                 
   High         279                      7.2                        2.10   1.62   2.73   \<.0001   279   7.4    2.11   1.43   3.12   .0002
  Tumor Stage                                                                                                                        
   Ta or Tis    253                      12.4                       1.00                           252   9.3    1.00                 
   T1           247                      7.7                        1.67   1.30   2.15   .0001     246   10.3   0.88   0.61   1.27   .50
  Lymph Nodes                                                                                                                        
   N0 or N~X~   487                      10.2                       1.00                           486   10.0   1.00                 
   N1           13                       2.7                        4.03   2.19   7.41   \<.0001   12    4.3    2.66   1.39   5.08   .003
  ANG                                                                                                                                
   0-2          408                      9.6                        1.00                           408   9.5    1.00                 
   3-4          29                       12.6                       0.75   0.42   1.35   .34       28    12.8   0.71   0.39   1.31   .28
  MMP-2                                                                                                                              
   0-2          175                      12.4                       1.00                           173   11.9   1.00                 
   3-4          281                      9.1                        1.40   1.06   1.84   .02       281   9.1    1.37   1.04   1.81   .03
   5-6          2                        6.6                        1.95   1.12   3.37             2     7.0    1.87   1.08   3.26   
  p53                                                                                                                                
   0-2          284                      10.4                       1.00                           284   9.5    1.00                 
   3-4          173                      9.7                        1.08   0.87   1.35   .49       173   10.6   0.89   0.70   1.13   .34
   5-6          24                       9.1                        1.17   0.75   1.82             24    11.7   0.80   0.49   1.28   
  Rb                                                                                                                                 
   0-2          114                      17.9                       1.00                           114   14.7   1.00                 
   3-4          313                      8.7                        2.25   1.72   2.95   \<.0001   312   9.2    1.76   1.34   2.31   .0001
   5-6          20                       4.2                        5.07   2.95   8.72             20    5.8    3.08   1.79   5.32   
  PAI-1                                                                                                                              
   0-2          192                      13.3                       1.00                           191   12.0   1.00                 
   3-4          277                      7.5                        1.90   1.48   2.43   \<.0001   277   8.1    1.61   1.23   2.09   .0004
   5-6          8                        4.3                        3.60   2.20   5.89             8     5.5    2.58   1.52   4.38   

^1^Univariate analyses are unadjusted. Multivariate analyses are adjusted for age, sex, tumor grade, tumor stage, and lymph nodes.

^2^Median is the median years overall survival as estimated from a parametric model.

^3^HR is the hazard ratio from a semiparametric (Cox proportional hazards) model. The 95% confidence limits (LCL and UCL) are shown.

^4^The expression p-values are for trend.

###### Overall Survival Results for Muscle Invasive Bladder Cancer

                Univariate Analyses^1^   Multivariate Analyses^1^                                                                 
  ------------- ------------------------ -------------------------- ------ ------ ------ ------- ----- ----- ------ ------ ------ ------
  Age (years)                                                                                                                     
   ≤ 65         176                      5.3                        1.00                         176   5.1   1.00                 
   \> 65        248                      3.3                        1.41   1.12   1.77   .004    248   3.4   1.38   1.10   1.74   .006
  Gender                                                                                                                          
   Female       130                      2.8                        1.00                         130   2.7   1.00                 
   Male         297                      4.7                        0.70   0.55   0.88   .002    294   4.7   0.68   0.54   0.86   .002
  Tumor Stage                                                                                                                     
   T2           382                      4.1                        1.00                         381   4.1   1.00                 
   T3 or T4     44                       3.7                        1.07   0.75   1.52   .73     43    3.5   1.11   0.76   1.60   .59
  Lymph Nodes                                                                                                                     
   N0 or N~X~   312                      4.6                        1.00                         309   4.6   1.00                 
   N1           115                      2.7                        1.40   1.09   1.81   .008    115   2.7   1.40   1.09   1.80   .009
  ANG                                                                                                                             
   0-2          318                      4.1                        1.00                         315   4.0   1.00                 
   3-4          35                       2.8                        1.26   0.84   1.88   .26     35    3.1   1.20   0.80   1.80   .37
  MMP-2                                                                                                                           
   0-2          190                      5.5                        1.00                         189   5.4   1.00                 
   3-4          150                      3.2                        1.48   1.18   1.86   .0008   148   3.3   1.44   1.14   1.83   .003
   5-6          6                        1.9                        2.19   1.38   3.46           6     2.0   2.08   1.29   3.33   
  p53                                                                                                                             
   0-2          140                      3.2                        1.00                         140   3.3   1.00                 
   3-4          186                      4.2                        0.84   0.71   1.00   .05     183   4.2   0.86   0.73   1.02   .09
   5-6          59                       5.6                        0.70   0.50   0.99           59    5.2   0.74   0.53   1.05   
  Rb                                                                                                                              
   0-2          39                       6.5                        1.00                         38    6.6   1.00                 
   3-4          311                      3.7                        1.43   1.03   2.00   .03     309   3.7   1.48   1.07   2.03   .02
   5-6          11                       2.1                        2.06   1.06   4.00           11    2.1   2.18   1.15   4.13   
  PAI-1                                                                                                                           
   0-2          143                      5.3                        1.00                         142   5.0   1.00                 
   3-4          228                      3.5                        1.37   1.11   1.70   .003    226   3.5   1.30   1.05   1.62   .02
   5-6          16                       2.3                        1.88   1.23   2.88           16    2.5   1.69   1.09   2.62   

^1^Univariate analyses are unadjusted. Multivariate analyses are adjusted for age, sex, tumor stage, and lymph nodes.

^2^Median is the median years overall survival as estimated from a parametric model.

^3^HR is the hazard ratio from a semiparametric (Cox proportional hazards) model. The 95% confidence limits (LCL and UCL) are shown.

^4^The expression p-values are for trend.
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DISCUSSION {#s3}
==========

In this retrospective analysis, we demonstrated that the expression of MMP-2, RB and PAI-1 correlated with a reduction in recurrence-free survival and overall survival in patients with BCa. Our results also demonstrated the prognostic value of combining ANG, MMP-2, p53, RB and PAI-1 expression for all patients with BCa. Thus, patients whose bladder tumors express these biomarkers may benefit from early radical treatment and/or neoadjuvant or adjuvant therapies. To the best of our knowledge, this represents the largest and most comprehensive study to date demonstrating the prognostic significance of MMP-2, RB and PAI-1 in patients with BCa.

The biomarkers that comprised this prognostic signature (*i.e.,* ANG, MMP-2, p53, RB and PAI-1) have a varied range of ascribed functions including angiogenesis, breakdown of extracellular matrix, serine protein inhibitor, DNA binding and transcription factor. ANG and PAI-1 \[[@R22]--[@R26]\] have also been associated with angiogenesis. Angiogenesis, the development of new blood vessels from existing blood vessels, is essential for normal growth and the development of tissues and organs. Furthermore, in addition to the degradation extracellular matrix by MMP-2, recent studies have suggested that ANG and PAI-1 can breakdown the extracellular matrix \[[@R27], [@R28]\]. Degradation of the extracellular matrix allows cells to become more motile. Thus, these extracellular matrix-degrading proteins may work in conjunction with an increase in vasculature, thereby, increasing the probability that motile-invasive tumor cells may enter the circulation to disseminate to distant organs \[[@R29]\]. P53 has both transactivation and transrepression activity and, thus, controls the transcription of numerous genes \[[@R30]--[@R32]\]. RB also controls the expression of numerous genes although it does so primarily by recruiting transcription factors and chromatin remodelling proteins \[[@R33]--[@R35]\]. Furthermore, we have identified that ANG regulates MMP-2 \[[@R17]\], as well as PAI-1 and p53 expression, \[[@R36]\] while PAI-1 activity is controlled by p53 and RB \[*unpublished data*\].

Previous *in vitro* and *in vivo* analyses of ANG and PAI-1 began to unravel their potential contributions to BCa pathobiology. Briefly, there is clear evidence that ANG expression positively regulates MMP-2 expression *via* ERK1/2 signaling \[[@R17]\]. In addition, ANG regulates MMP-2 expression through two major pathways, a) p53 regulation *via* ERK pathway activation and b) induction of hypomethylation by DNMT3b down-regulation through the ERK pathway \[[@R36]\]. MMPs are known to affect extracellular matrix (ECM) remodeling, angiogenesis, apoptosis, epithelial-to-mesenchymal transition and cell proliferation and, thus, induce aggressive invasion and metastasis of different cancer types, including BCa \[[@R37]\]. Assessing the GEO database, we found that MIBC specimens had increased levels of ANG and MMP-2 compared to NMIBC. These findings suggest ANG may influence MMP-2 gene, which may be a mechanism to promote BCa growth and angiogenesis. Interestingly in the current study, ANG expression was not associated with tumor grade or tumor stage. Perhaps the inability to probe for ANG was due to the condition of the paraffin embedded tissue (*i.e.,* older sections may have some degradation of proteins). Thus, more research is needed to confirm ANG's presence in human BCa. On the other hand, MMP-2 expression was greater in low-grade and low-stage BCa and was associated with a reduction in recurrence-free survival as well as reduction in overall survival.

PAI-1 is the primary inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), and it acts to suppress tissue and plasma fibrinolysis *via* plasmin conversion \[[@R38]\]. We found that the down-regulation of PAI-1 led to a) an inhibition in cell proliferation and b) a potent arrest in the G~1~ to S phase of the cell cycle, a phenomena associated with reduction in cyclin D3/cdk4/6 and cyclin E/cdk2 and an increase in cell cycle inhibitors, p53, p21^Cip1/Waf1^, and p27^kip1^ \[[@R18]\]. Little attention has been given to PAI-1 in the human urinary bladder. For example, only two groups have reported PAI-1 levels for BCa patients. Urquidi *et al.* noted a significant increase in urothelial cell PAI-1 levels in patients bearing bladder tumors compared to non-tumor bearing patients \[[@R39]\]. Becker *et al.* reported significantly higher PAI-1 levels in tissue and plasma samples, but not in urine, from patients with BCa compared with controls \[[@R40]\]. Although the function of PAI-1 is complex, further investigation is warranted in the hope that it can provide insight into specific aspects of tumor biology and the identification of tumor cell vulnerabilities for therapeutic exploitation. Interestingly in the current study, higher PAI-1 expression was associated with high-grade compared to low-grade, while higher expression of p53 and RB were associated with high-grade and high stage disease. High PAI-1, p53 and RB were associated with a reduction in survival. Perhaps, the ability to demonstrate the difference in PAI-1 expression in this cohort compared to our previous cohort is related to the increase in the sample sizes of the current study. The high expression levels of p53 and RB have been well documented in BCa \[[@R41], [@R42]\]. In fact several studies have reported on the prognostic significance of p53 expression in bladder tumors. For example, Cordon-Cardo and others, noted an association between the p53-positive phenotype and disease progression (p \< 0.001), as well as reduced survival (p \< 0.001) in a small cohort comprised of 29 NMIBC \[[@R43]\]. Similarly in MIBC, Shariat and others, reported that alteration in p53 (or p21, pRB, p16) was independently associated with disease progression (p ≤ 0.038) and disease-specific survival (p *\<* 0.039) in a small cohort of 127 MIBC treated with cystectomy \[[@R44]\]. Differences in outcomes associated with these studies and the current study may be related to our large, diverse cohort of 939 subjects. In the only phase III randomized study assessing the prognostic significance of p53 in BCa, Stadler and others, could not validate the prognostic significance of p53 in 521 patients undergoing adjuvant chemotherapy \[[@R45]\]. However, the current report begins to elucidate a specific pathway involving PAI-1, p53 and RB in human BCa. On the other hand, MMP-2 expression was greater in low-grade and low-stage BCa and was associated with a reduction in recurrence-free survival, as well as a reduction in overall survival.

Our findings in this report also have therapeutic implications regarding the potential utility of targeting these proteins directly. We and others have previously reported that blocking ANG, MMP-2, p53, RB or PAI-1 in bladder cell lines can significantly reduce cell proliferation/survival \[[@R17], [@R18]\], migration and invasion \[[@R18], [@R45], [@R46]\] and angiogenesis \[[@R17], [@R47]--[@R49]\]. Our current results, when combined with these previous observations, further strengthen the rationale of targeting MMP-2, RB and PAI-1 directly for treatment of BCa.

In summary, we have demonstrated in this study that MMP-2, RB and PAI-1 expression is correlated with poor prognosis of patients with BCa. Our findings support the hypothesis that targeting these three molecules may improve the survival of patients with BCa.

MATERIALS AND METHODS {#s4}
=====================

Patients and clinicopathologic information {#s4_1}
------------------------------------------

The study was performed after approval by the Western Institutional Review Board under a request of waiver of consent on archived pathologic specimens. Tissue microarrays associated with two independent patient cohorts were used in the current study. Cohort \#1 was comprised of 587 patients diagnosed with BCa from 1979-2007 at Aarhus University Hospital (Aarhus, Denmark) \[[@R21]\], including 2 sub-cohorts; one with 223 primary Ta/T1 tumors from patients treated by transurethral resection of the bladder and one with 364 tumors from radical cystectomy patients. Cohort \#2 was comprised of 352 patients diagnosed with BCa from 1984-2005 at Uppsala University Hospital (Uppsala, Sweden) \[[@R50]\]. Thus, samples from 939 patients were available for analysis. Demographic, clinical, disease and treatment characteristics are presented in Table [1](#T1){ref-type="table"}. The median follow-up for the entire cohort was 5.37 years.

Follow-up data also included progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS). The endpoints of recurrence-free survival and OS were calculated from the date of surgery to the date of the recurrence or last follow-up.

Immunohistochemcal staining of tissue microarrays {#s4_2}
-------------------------------------------------

Immunostaining was performed using standard protocols. TMAs were deparaffinized in xylene and rehydrated using graded percentages of ethanol followed by antigen retrieval with citric acid buffer (pH 6.0, 95°C for 20 min). The slides were treated with 3% hydrogen peroxide in water to block endogenous peroxidase activity. Staining for ANG, MMP-2, p53, RB and PAI-1 was conducted using mouse anti-human ANG antibody (C-1; 1:25 dilution in blocking buffer, Santa Cruz Biotechnology), rabbit anti-MMP-2 antibody (AB19167; 1:100 dilution in Biocare Background Sniper, EMD Millipore), mouse anti-p53 antibody (NCL-L-p53-DO7; 1:100 dilution in Biocare Background Sniper, Leica Biosystems), rabbit anti-Rb Antibody (C-15; 1:500 dilution in Biocare Background Sniper, Santa Cruz Biotechnology), and rabbit anti-PAI-1 antibody (HPA050039; 1:100 dilution in blocking buffer, Sigma-Aldrich), respectively. The antibodies\' specificity information can be found in the manufacturers' datasheets or our previous publication \[[@R20]\]. Biotin-labeled horse anti-mouse IgG (2 μg/ml in blocking buffer, Vector Laboratories) was used as the secondary antibody. Immunoreactive signals were amplified by the formation of avidin-biotin peroxidase complexes and visualized using 3, 3\'- diaminobenzidine (DAB). Nuclear counterstaining was conducted with hematoxylin.

The expression levels of ANG, MMP-2, p53, RB and PAI-1 were scored by assigning a proportion score and an intensity score \[[@R17], [@R18], [@R51], [@R52]\]. The estimated proportion (0 = 0% of cells; 1 = 1% to 40%; 2 = 41% to 75% and 3 = 76% to 100%) and the average intensity (0 = none; 1 = weak; 2 = intermediate and 3 = strong) of immunoreactive tumor cells were assessed. The proportion and intensity scores were combined to obtain a total staining score for each protein, which ranged from 0 to 6. Thus, the protein expression levels were determined based on the total ANG, MMP-2, p53, RB and PAI-1 staining score as follows: none = 0, low = 1 or 2, moderate = 3 or 4, high = 5 or 6. Two investigators (OTMC, YS), who were blinded to the clinicopathologic data and clinical outcomes, scored each core. When there was a discrepancy in the scoring, a third investigator reviewed consensus scoring was obtained.

Human lung (SERPINE1, MMP-2), liver (ANG) and tonsil (p53, Rb) were used as positive controls, and omitting the primary antibody served as the negative controls.

Statistical analysis {#s4_3}
--------------------

SAS 9.4 (Cary, NC) was used to perform the statistical analyses. The relationship between immunoexpression of the five targets and clinicopathological features were assessed with the Fisher's exact test (crosstabs), log-rank tests (progression-free survival, cancer-specific survival and overall survival), and multivariate Cox proportional hazards regression (used to adjust for demographic and clinical parameters). All tests were 2-tailed.

SUPPLEMENTARY MATERIALS FIGURE AND TABLES {#s5}
=========================================
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